Tarsus Pharmaceuticals, Inc.

TARS Net selling

CIK 0001819790 #1728 in the set updated 17 Sep 2026

Bought (120 mo)

$16.53M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$65.89M

$18.07M on a plan · $167.75K straight out of an exercise

Sold at will

$47.66M

191 of 257 sales

Net

−$49.37M

−$31.13M against sales at will

By person

24 insiders · 271 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Azamian Bobak R.

President/CEO and Board Chair

—

$15.04M (88) scheduled

−$15.04M

1,709,403

3.90%

$145.30M

−19.0%

RTW INVESTMENTS, LP entity

10% owner

—

$13.49M (1)

−$13.49M

2,013,601

4.59%

$171.16M

−18.3%

Vivo Capital IX, LLC entity

10% owner

$4.00M (1)

$14.46M (10)

−$10.46M

8,701,367

19.83%

$739.62M

+39.6%

LINK WILLIAM J PHD

Director

—

$5.96M (13) scheduled

−$5.96M

1,219,087

2.78%

$103.62M

−2.2%

Frazier Life Sciences IX, L.P.

10% owner

$5.00M (1)

—

+$5.00M

1,917,157

4.37%

$162.96M

—

Whitfield Dianne C.

Chief Human Resources Officer

—

$3.36M (22) scheduled

−$3.36M

35,028

0.0798%

$2.98M

+1,675%

Horowitz Limited Partnership VIII entity

10% owner

$2.95M (2)

—

+$2.95M

1,987,105

4.53%

$168.90M

—

Mottiwala Aziz

Chief Commercial Officer

—

$2.87M (25)

−$2.87M

61,480

0.1401%

$5.23M

+8.3%

Tester Jason E.

Director

$2.75M (2)

—

+$2.75M

1,949,331

4.44%

$165.69M

—

Neervannan Seshadri

Chief Operating Officer

—

$2.54M (16)

−$2.54M

79,482

0.1811%

$6.76M

+41.9%

Farrow Jeffrey S

See Remarks

—

$2.33M (9)

−$2.33M

56,801

0.1294%

$4.83M

+8,014%

Lin Elizabeth Yeu

Chief Medical Officer

$456.31K (3)

$2.40M (12) scheduled

−$1.95M

32,043

0.0730%

$2.72M

+102.0%

Wahl Bryan

General Counsel

—

$1.67M (17)

−$1.67M

63,959

0.1457%

$5.44M

+537.0%

Greenstein Leonard M.

Chief Financial Officer

—

$708.04K (16)

−$708.04K

26,785

0.0610%

$2.28M

−61.3%

Ackermann Michael

Director

$1.35M (1)

$752.39K (16)

+$597.61K

1,308,273

2.98%

$111.20M

+12.2%

Goodrich Katherine

Director

—

$183.38K (1) scheduled

−$183.38K

2,233

0.0051%

$189.81K

—

Trevejo Jose M.

CHIEF MEDICAL OFFICER

—

$113.02K (8) scheduled

−$113.02K

2,251

0.0051%

$191.34K

+40.3%

Goldberg Andrew D.

Director

$18.96K (1)

—

+$18.96K

19,654

0.0448%

$1.67M

—

Holdbrook Mark J.

V.P., Clinical Affairs

—

$7.50K (3)

−$7.50K

3,191

0.0073%

$271.24K

+187.2%

YARNO WENDY L

Director

—

—

—

16,654

0.0380%

$1.42M

—

CHAUDHURI BHASKAR

Director

—

—

—

11,654

0.0266%

$990.59K

—

Morrison Scott W

Director

—

—

—

7,638

0.0174%

$649.23K

—

Crane Rosemary A

Director

—

—

—

5,350

0.0122%

$454.75K

—

PYOTT DAVID E I

Director

—

—

—

1,383

0.0032%

$117.56K

—

Individual transactions

3

Insider

Date

Role

Action

Shares

Price

Amount

Goldberg Andrew D.

7 Mar 2025

Director

Exercised, kept

7,000

$12.89

$90.23K

Mottiwala Aziz

24 Aug 2022

Chief Commercial Officer

Exercised, kept

772

$0.45

$347.40

Mottiwala Aziz

24 Aug 2022

Chief Commercial Officer

Exercised, kept

4,416

$10.99

$48.53K

Showing 250 of 271 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 300

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 8

Sales on a Rule 10b5-1 plan 64

Sales straight out of an exercise 2

Sales at will 191

Transactions with no price 0

Shares from compensation/vesting 11,492,783

Sales filed before the plan box existed 99

History held since 20 Oct 2020